Home A Pediatric Endocrinologist's View Of MannKind's Afrezza
 

Keywords :   


A Pediatric Endocrinologist's View Of MannKind's Afrezza

2015-11-05 13:08:14| Biotech - Topix.net

There have been many investment analyst opinions expressed about the coming success or failure of MannKind Corporation's new inhaled insulin, Afrezza. Sanofi , MannKind's pharmaceutical marketing partner, has invested millions of dollars in up front licensing fees, milestone payments, and Afrezza related costs in marketing and promotion.

Tags: view pediatric afrezza

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Producers to be paid grid premiums for AngusLink beef scores
18.05This Week in Agribusiness, May 18, 2024
18.05This Week in Agribusiness, May 18, 2024
18.05Unpaid carers being forced to repay 250m to DWP
18.05Weekly Recap: Hempel, Axalta, KANSAI HELIOS Top This Weeks Stories
18.05Eastern North Pacific Tropical Weather Outlook
More »